– $80 million Series B funding secured by Charm Therapeutics.
– AI-designed cancer drug to enter clinic early next year.
Charm Therapeutics UK secures $80 million in Series B funding to advance its AI-designed cancer drug into clinical trials by early next year. The London-based biotech, co-founded by Nobel laureate David Baker, aims to leverage artificial intelligence to accelerate drug discovery and development.
The funding round is led by Nvidia, a leader in AI technology, and includes participation from several other investors. This investment will support the clinical development of Charm’s lead candidate, which targets a specific cancer pathway. The company plans to initiate trials with a focus on safety and efficacy in a select patient population.
Charm Therapeutics utilizes AI to design molecules that can effectively target cancer cells while minimizing side effects. This approach aims to improve the precision and speed of drug development. The company is part of a growing trend of biotech firms using AI to enhance traditional drug discovery methods.
The $80 million funding will also enable Charm to expand its research team and infrastructure. This expansion is crucial for advancing its pipeline and bringing innovative treatments to patients faster. The company is poised to make significant strides in the oncology space with this financial backing.
For more information on Charm Therapeutics and their innovative approach, visit their official announcement. To learn more about the latest developments in clinical trials, explore our Clinical Trials & R&D section.